- News

"Treating Tau: Finally, Clinical Candidates Are Stepping into the Ring"

Read a detailed conference report on our clinical tau modifier presented at AD/PD 2017

- Press releases

Asceneuron Receives Approval for Phase I Study of Oral Tau Inhibitor

Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor
First-in-human trial of novel inhibitor targeting accumulation of toxic neurofibrillary tau tangles to fight neurodegenerative diseases including dementia

- Event

Asceneuron to participate in the 1st EuroTauMeeting

Asceneuron to participate in the 1st EuroTauMeeting or how to know everything about Tau protein and associated diseases in Lille, France, on April 27-28, 2017.

- Event

Asceneuron to present at the AD/PD Conference in Vienna

Asceneuron to present at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases on 29 March 2017 in Vienna, Austria.

- Press releases

J. Michael Ryan, M.D. appointed as Chief Medical Officer

Asceneuron today announced the appointment of J. Michael Ryan, M.D. as Chief Medical Officer. With over 15 years of Central Nervous System (CNS) clinical research experience, Michael brings extensive drug development expertise to Asceneuron. He will be responsible for advancing Asceneuron’s pipeline of innovative small molecules and progressing tau modifiers through the clinic.

- Event

Asceneuron to attend 2017 J.P. Morgan Healthcare Conference

Asceneuron to attend the 35th Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2017 at the Westin St. Francis in San Francisco, CA.

- Event

Asceneuron to present a poster on the M1 PAM program

Asceneuron will present a poster on the M1 PAM program at the Society for Neuroscience (SfN) Annual Meeting 2016 on November 12-16, 2016 in San Diego, USA.

- Press releases

Asceneuron receives grant from The Michael J. Fox Foundation for Parkinson’s research

Asceneuron has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research for the further development of positive allosteric modulators of the M1 muscarinic acetylcholine receptor.

- Event

Meet Asceneuron at Bio-Europe 2016

Asceneuron to attend Bio-Europe partnering event on 7-9 November, 2016 in Cologne, Germany

- Event

Asceneuron to present at the 6th FTD UK Annual Meeting 2016

Asceneuron to present at the 6th FTD UK Annual Meeting 2016 on November 4, 2016 in Cambridge, United Kingdom.